Overview

Efficacy and Safety of Desmopressin (Nocturin®) 0.1 mg Tablets in Treatment of Nocturia in Participants With Benign Prostate Syndrome (BPS)

Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
0
Participant gender:
Male
Summary
Documentation of the efficacy and safety of desmopressin (Nocturin®) 0.1 mg tablet. Observation of patients with benign prostate syndrome, in whom nocturia associated with nocturnal polyuria is treated with desmopressin (Nocturin®) 0.1 mg tablet focusing on number of nocturnal voids, ratio of night/24-h urine volume (%), duration of first undisturbed sleep period and quality of life.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Ferring Pharmaceuticals
Treatments:
Deamino Arginine Vasopressin
Criteria
Inclusion Criteria:

- Therapeutic need according to Summary of Product Characteristics

- Written informed consent

Exclusion Criteria:

- Contraindications according to Summary of Product Characteristics